BioCatalyst

Deucravacitinib — catalyst calendar

3 verified catalyst event(s) referencing Deucravacitinib, each linked to its official source. Verified as of 2026-08-06.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-10-19
in 2mo
ESTIMATED
 READOUT
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Plac
Phase 3 · Systemic Lupus Erythematosus
 BMY BRISTOL MYERS SQUIBB CO Deucravacitinib ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
2026-10-19
in 2mo
ESTIMATED
 READOUT
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Com
Phase 3 · Systemic Lupus Erythematosus
 BMY BRISTOL MYERS SQUIBB CO Deucravacitinib ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
2026-11-18
in 3mo
ESTIMATED
 READOUT
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Ac
Phase 3 · Sjögren's Syndrome
 BMY BRISTOL MYERS SQUIBB CO Deucravacitinib ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.